HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

RANKL signaling and osteoclastogenesis is negatively regulated by cardamonin.

Abstract
Bone loss/resorption or osteoporosis is a disease that is accelerated with aging and age-associated chronic diseases such as cancer. Bone loss has been linked with human multiple myeloma, breast cancer, and prostate cancer and is usually treated with bisphosphonates, and recently approved denosumab, an antibody against receptor activator of NF-κB ligand (RANKL). Because of the numerous side effects of the currently available drugs, the search continues for safe and effective therapies for bone loss. RANKL, a member of the TNF superfamily, has emerged as a major mediator of bone loss via activation of osteoclastogenesis. We have identified cardamonin, a chalcone isolated from Alpinia katsumadai Hayata that can affect osteoclastogenesis through modulation of RANKL. We found that treatment of monocytes with cardamonin suppressed RANKL-induced NF-κB activation and this suppression correlated with inhibition of IκBα kinase and of phosphorylation and degradation of IκBα, an inhibitor of NF-κB. Furthermore, cardamonin also downregulated RANKL-induced phosphorylation of MAPK including ERK and p38 MAPK. Cardamonin suppressed the RANKL-induced differentiation of monocytes to osteoclasts in a dose-dependent and time-dependent manner. We also found that an inhibitor of NF-κB essential modulator (NEMO) blocked RANKL-induced osteoclastogenesis, indicating a direct link with NF-κB. Finally, osteoclastogenesis induced by human breast cancer cells or human multiple myeloma cells were completely suppressed by cardamonin. Collectively, our results indicate that cardamonin suppresses osteoclastogenesis induced by RANKL and tumor cells by suppressing activation of the NF-κB and MAPK pathway.
AuthorsBokyung Sung, Sahdeo Prasad, Vivek R Yadav, Subash C Gupta, Simone Reuter, Norio Yamamoto, Akira Murakami, Bharat B Aggarwal
JournalPloS one (PLoS One) Vol. 8 Issue 5 Pg. e64118 ( 2013) ISSN: 1932-6203 [Electronic] United States
PMID23691159 (Publication Type: Journal Article)
Chemical References
  • Chalcones
  • NF-kappa B
  • Oligonucleotides
  • RANK Ligand
  • TNFSF11 protein, human
  • I-kappa B Kinase
  • cardamonin
  • Trypan Blue
Topics
  • Animals
  • Blotting, Western
  • Bone Resorption (drug therapy)
  • Cell Line, Tumor
  • Chalcones (pharmacology)
  • Dose-Response Relationship, Drug
  • Electrophoretic Mobility Shift Assay
  • Humans
  • I-kappa B Kinase (metabolism)
  • Mice
  • Monocytes (drug effects)
  • NF-kappa B (metabolism)
  • Oligonucleotides (genetics)
  • Osteoclasts (cytology, drug effects)
  • Phosphorylation (drug effects)
  • RANK Ligand (metabolism)
  • Signal Transduction (drug effects, physiology)
  • Trypan Blue

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: